Bolt Biotherapeutics (BOLT) Expected to Announce Earnings on Tuesday

Bolt Biotherapeutics (NASDAQ:BOLT) is expected to post its Q3 2025 results before the market opens on Tuesday, November 11th. Analysts expect Bolt Biotherapeutics to post earnings of ($5.08) per share for the quarter. Parties may review the information on the company’s upcoming Q3 2025 earningreport for the latest details on the call scheduled for Friday, November 14, 2025 at 4:00 PM ET.

Bolt Biotherapeutics (NASDAQ:BOLT) last announced its earnings results on Thursday, August 14th. The company reported ($4.46) earnings per share (EPS) for the quarter, beating the consensus estimate of ($6.40) by $1.94. The company had revenue of $1.80 million for the quarter, compared to analysts’ expectations of $0.82 million. On average, analysts expect Bolt Biotherapeutics to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Bolt Biotherapeutics Stock Down 2.3%

Shares of NASDAQ:BOLT traded down $0.13 during mid-day trading on Tuesday, hitting $5.45. 11,001 shares of the company traded hands, compared to its average volume of 17,636. The stock has a market cap of $10.46 million, a P/E ratio of -0.20 and a beta of 0.92. The company has a current ratio of 3.11, a quick ratio of 3.11 and a debt-to-equity ratio of 0.56. Bolt Biotherapeutics has a 12-month low of $4.59 and a 12-month high of $13.80. The stock has a 50-day moving average price of $5.51 and a two-hundred day moving average price of $5.94.

Analyst Ratings Changes

BOLT has been the topic of several analyst reports. HC Wainwright set a $7.00 target price on Bolt Biotherapeutics and gave the company a “buy” rating in a research report on Monday, October 20th. Lake Street Capital boosted their price objective on Bolt Biotherapeutics to $75.00 and gave the stock a “buy” rating in a research report on Friday, August 15th. Zacks Research raised Bolt Biotherapeutics from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, October 22nd. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Bolt Biotherapeutics in a research report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $34.00.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.